REG - Hikma Pharmaceutical - Director/PDMR Shareholding
09/05/2024 10:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240509:nRSI7975Na&default-theme=true
RNS Number : 7975N Hikma Pharmaceuticals Plc 09 May 2024
Hikma Pharmaceuticals PLC
(the "Company")
LONDON, 9 May 2024: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)
(LEI: 549300BNS685UXH4JI75) announces that the below listed Persons
Discharging Managerial Responsibility ("PDMRs") of the Company acquired
Ordinary Shares in the Company, which were purchased under a dividend
reinvestment plan ("DRIP").
This notification is made under Article 19(1) of the EU Market Abuse
Regulation 596/2014 as it forms part of domestic law by virtue of the European
Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided
in accordance with the requirements of Article 19(3) of MAR.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities
Riad Mishlawi
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Riad Mishlawi
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Acquisition of Ordinary Shares through participation in a DRIP.
c) Price(s) and volume(s) Price(s) Volume(s)
£19.79 736
d) Aggregated information Price(s): £19.79
Volume(s): 736
Total: £14,564.29
e) Date of the transaction 7 May 2024
f) Place of the transaction London Stock Exchange (XLON)
Susan Ringdal
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Susan Ringdal
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Acquisition of Ordinary Shares through participation in a DRIP.
c) Price(s) and volume(s) Price(s) Volume(s)
£19.79 180
d) Aggregated information Price(s): £19.79
Volume(s): 180
Total: £3,561.92
e) Date of the transaction 7 May 2024
f) Place of the transaction London Stock Exchange (XLON)
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Acquisition of Ordinary Shares through participation in a DRIP.
c) Price(s) and volume(s) Price(s) Volume(s)
£19.34 726
d) Aggregated information Price(s): £19.34
Volume(s): 726
Total: £14,040.84
e) Date of the transaction 3 May 2024
f) Place of the transaction London Stock Exchange (XLON)
Hussein Arkhagha
1 Details of the person discharging managerial responsibilities / person
closely associated
a) Name Hussein Arkhagha
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type
of instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Acquisition of Ordinary Shares through participation in a DRIP.
c) Price(s) and volume(s) Price(s) Volume(s)
£19.79 297
d) Aggregated information Price(s): £19.79
Volume(s): 297
Total: £5,877.17
e) Date of the transaction 7 May 2024
f) Place of the transaction London Stock Exchange (XLON)
4 Details of the transaction(s): section to be repeated for (i) each type
of instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Acquisition of Ordinary Shares through participation in a DRIP.
c) Price(s) and volume(s) Price(s) Volume(s)
£19.34 150
d) Aggregated information Price(s): £19.34
Volume(s): 150
Total: £2,901.00
e) Date of the transaction 3 May 2024
f) Place of the transaction London Stock Exchange (XLON)
Julie Hill
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Julie Hill
2 Reason for the notification
a) Position/status PDMR
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Acquisition of Ordinary Shares through participation in a DRIP.
c) Price(s) and volume(s) Price(s) Volume(s)
£19.79 59
d) Aggregated information Price(s): £19.79
Volume(s): 59
Total: £1,167.52
e) Date of the transaction 7 May 2024
f) Place of the transaction London Stock Exchange (XLON)
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction Acquisition of Ordinary Shares through participation in a DRIP.
c) Price(s) and volume(s) Price(s) Volume(s)
£19.34 1
d) Aggregated information Price(s): £19.34
Volume(s): 1
Total: £19.34
e) Date of the transaction 3 May 2024
f) Place of the transaction London Stock Exchange (XLON)
Helen Middlemist
Group Company Secretary
+44 (0) 20 7399 2760
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHGIGDUISGDGSCRecent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Result of AGM
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Hikma appoints new President of Generics business
Announcement